Pseudomonas Aeruginosa Infection Treatment Market size was valued at USD 1.31 Billion in 2022 and is projected to reach USD 2.11 Billion by 2030, growing at a CAGR of 6.9% from 2023 to 2030.

Pseudomonas aeruginosa has a prevalence of 7.1%–7.3% among all healthcare-associated infections. The most common site of this infection is pneumonia, and it is the most common Gram-negative organism identified in nosocomial pneumonia. The prevalence of P. aeruginosa is been increasing at a very faster rate. Moreover, if seen in intensive care unit (ICU) patients, these bacteria are responsible for an even higher percentage of healthcare-associated infections. A large international observational point-prevalence study of infections in ICU patients found that Pseudomonas aeruginosa represented around 16.2% of patient infections and was the cause of 23% of all ICU-acquired infections, with a respiratory source being the most common site of this infection.

https://introspectivemarketresearch.com/request/16572

The Report Will Include A Major Chapter

·         Patent Analysis

·         Regulatory Framework

·         Technology Roadmap

·         BCG Matrix

·         Heat Map Analysis

·         Price Trend Analysis

·         Investment Analysis

Market Dynamics and Factors:  

The rising number of P. aeruginosa cases across the world is the primary factor that is boosting the demand for P. aeruginosa infection treatment. Today, Pseudomonas aeruginosa is one of the most common pathogens that may prove fatal, these bacteria cause severe nosocomial infections and also it is well-known for their multidrug resistance and hypervirulence. Infections caused by P. aeruginosa are critical to curate routinely.

Scope of the Report:

The latest report on the Pseudomonas Aeruginosa Infection Treatment Market provides a detailed analysis of the market for the years 2023 to 2030. It presents a comprehensive overview of the global Pseudomonas Aeruginosa Infection Treatment Market industry, incorporating all key industry trends, market dynamics, competitive landscape, and market analysis tools such as Porter's five forces analysis, Industry Value chain analysis, and PESTEL analysis of the Pseudomonas Aeruginosa Infection Treatment Market. Moreover, the research covers crucial chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to grasp the market direction and development in the present and forthcoming years.

Discount on the Research Report:

https://introspectivemarketresearch.com/discount/16572

Top Key Players Covered In The Pseudomonas Aeruginosa Infection Treatment Market:

Allergan (US),Pfizer Inc. (US),Merck & Co. Inc. (US),AstraZeneca PLC (UK),Novartis AG (Switzerland),Lupin Pharmaceuticals Inc. (India),Gilead Sciences Inc. (US),Teva Pharmaceutical Industries Ltd. (Israel),Bristol-Myers Squibb Co. (US),PARI Medical Holding GmbH (Germany),Janssen Pharmaceuticals Inc. (Belgium),AmpliPhi Biosciences Corp (US),Humanigen Inc (US) and Other Major Players

Key Industry Development:

In December 2021, Polyphor and EnBiotix Announced Dosing of First Patient in a First-in-Human Clinical Trial of Inhaled Murepavadin, a novel-class antibiotic. In the current Phase I study murepavadin Inhalation Solution (MIS) will be administered using an eFlow ^ (R) Technology nebulizer (PARI Pharma GmbH) to investigate the safety, tolerability, and pharmacokinetics of murepavadin in healthy volunteers. It is also said that inhaled murepavadin has the potential to provide a significant advancement in the treatment of CF patients with chronic Pseudomonas aeruginosa.

In May 2021, Teva Pharmaceutical Industries Ltd., a leading multinational pharmaceutical company introduced erythromycin tablets. The company has launched medicines with the strength of 250 mg and 500 mg. Erythromycin tablets are prescribed to the patients with the bacterial infections as well as rheumatic fever and those who have an allergy to penicillin.

In April 2021, CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia that is caused by Pseudomonas aeruginosa, a serious problem in hospitals and intensive-care units. Pseudomonas aeruginosa is one of the top three antibiotic-resistant bacteria listed by the WHO as ‘priority pathogens’. The CARB-X provided around $5.3 million to support preclinical development of Phico’s SASPject PT3.9 project, plus up to $12.86 million more if the project goes successfully through safety to Phase 1 first-in-human clinical studies.

Faster Payment Service (FPS) Market Segmentation:

By Treatment Type

·         Monotherapy

·         Combination Therapy

By Drug Type

·         Cephalosporin

·         Aminoglycoside

·         Carbapenem

·         Monobactam

·         Others

By Route of Administration

·         Nasal

·         Oral

·         Intravenous

By Distribution Channel

·         Hospital Pharmacy

·         Retail Pharmacy

·         Online Pharmacy

For this report, Introspective Market Research has segmented thePseudomonas Aeruginosa Infection Treatment Market based on region:

§  North America (U.S., Canada, Mexico)

§  Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

§  Western Europe (Germany, U.K., France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

§  Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

§  Middle East & Africa (Turkey, Saudi Arabia, Bahrain, Kuwait, Qatar, UAE, Israel, South Africa)

§  South America (Brazil, Argentina, Rest of SA)

Covid-19 Impact Analysis on Pseudomonas Aeruginosa Infection Treatment Market:

COVID-19 both directly and indirectly has affected hugely on mankind, although the mortality rate of the coronavirus is as low as 3%-4%, SARS-CoV-2 is known to rapidly decimate and lead to a high rate of hospitalization due to its high speed of propagation. And hence such hospital admissions during the pandemic period eventually led the patients to face hospital-acquired infections as, the coronavirus disease could put patients, particularly those having severe pneumonia, at risk of some well-known nosocomial pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, baumannii and P. aeruginosa are among the most successful nosocomial pathogens with respective mortality rates of up to 70% and 61%.

Acquire the Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16572

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1 773 382 1049